Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis
Yuhao Liu,Ying Zhao,Yousef Shukha,Haocheng Lu,Lu Wang,Zhipeng Liu,Cai Liu,Yang Zhao,Huilun Wang,Guizhen Zhao,Wenying Liang,Yanbo Fan,Lin Chang,Arif Yurdagul,Christopher B Pattillo,A Wayne Orr,Michael Aviram,Bo Wen,Minerva T Garcia-Barrio,Jifeng Zhang,Wanqing Liu,Duxin Sun,Tony Hayek,Y Eugene Chen,Oren Rom,Christopher B. Pattillo,A. Wayne Orr,Minerva T. Garcia-Barrio,Y. Eugene Chen
DOI: https://doi.org/10.1016/j.celrep.2021.109420
IF: 8.8
2021-07-01
Cell Reports
Abstract:Dysregulated glycine metabolism is emerging as a common denominator in cardiometabolic diseases, but its contribution to atherosclerosis remains unclear. In this study, we demonstrate impaired glycine-oxalate metabolism through alanine-glyoxylate aminotransferase (AGXT) in atherosclerosis. As found in patients with atherosclerosis, the glycine/oxalate ratio is decreased in atherosclerotic mice concomitant with suppression of AGXT. Agxt deletion in apolipoprotein E-deficient (Apoe−/−) mice decreases the glycine/oxalate ratio and increases atherosclerosis with induction of hepatic pro-atherogenic pathways, predominantly cytokine/chemokine signaling and dysregulated redox homeostasis. Consistently, circulating and aortic C-C motif chemokine ligand 5 (CCL5) and superoxide in lesional macrophages are increased. Similar findings are observed following dietary oxalate overload in Apoe−/− mice. In macrophages, oxalate induces mitochondrial dysfunction and superoxide accumulation, leading to increased CCL5. Conversely, AGXT overexpression in Apoe−/− mice increases the glycine/oxalate ratio and decreases aortic superoxide, CCL5, and atherosclerosis. Our findings uncover dysregulated oxalate metabolism via suppressed AGXT as a driver and therapeutic target in atherosclerosis.
cell biology